As part of the Governor’s domestic mission trip, Governor Reynolds met with leaders from Bora Group to discuss onshoring pharmaceutical manufacturing, strengthening supply chain integration across the Midwest, and expanding contract development and manufacturing.
“This is a great example of how Iowa can lead the nation in revitalizing domestic manufacturing and strengthening critical industries,” said Governor Kim Reynolds. “Bora Group and Upsher-Smith are investing in people, innovation, and infrastructure; the very pillars of the high-value growth we’re driving in Iowa. By fostering regional partnerships and expanding U.S. supply chains, we’re not only advancing healthcare – we’re creating jobs, fueling economic growth, and enhancing long-term competitiveness for our states.”
The visit began with a tour of the Maple Grove manufacturing facility and a forward-looking discussion about growing domestic manufacturing and CDMO (Contract Development and Manufacturing) opportunities – both critical components of a resilient pharmaceutical supply chain. Bora group CDMO leaders shared insights into the company’s integrated global network, pharmaceutical development and manufacturing capabilities, and vision for expanding CDMO partnerships in the U.S..
“Bora Pharmaceuticals is deeply committed to strengthening pharmaceutical manufacturing here in the U.S.” said Dennis Hall, Vice President of Bora Pharmaceuticals. “As a global CDMO with a growing domestic footprint, we see tremendous opportunity for investment, innovation, and collaboration. We appreciate leaders like Governor Reynolds who understand the critical role of a resilient, U.S.-based supply chain in ensuring patients have consistent access to essential medicines.”
Additionally, during the roundtable, executives from Upsher-Smith highlighted the Company’s branded portfolio and its impact on patient care through high-quality medications, including treatments for pediatric rare diseases.
Discussions also focused on Bora’s robust production capabilities in the U.S. and ongoing commitment to onshoring operations. Such was reiterated at the premise of Bio Asia, where J.D. Mowery, CDMO Division President of Bora Pharmaceuticals, presented “Taiwan Pharma’s Path to U.S. Market Success”. To date, the company has invested hundreds of millions of dollars in U.S. domestic infrastructure with continuous CAPEX plans.
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate